Neuraxis, Inc. (NRXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $68.13M
Last updated: Nov 17, 2026 at 4:23 PM ET
Neuraxis, Inc. (NRXS) Statistics
Neuraxis (NRXS) has a market cap of $68.13M and an enterprise value of $63.86M. It kept -185.24% of revenue as net income over the last 12 months. Its share count is up 31.45% from a year earlier.
Total Valuation
Enterprise value is 6.27% below the market cap, as cash exceeds debt.
| Market Cap | $68.13M |
|---|---|
| Enterprise Value | $63.86M |
| Latest price (Nov 17, 2026) | $4.62 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 9.2x and 16.6x. Its year-end P/S ranged from 5.8x to 11.0x from 2023 to 2025.
| P/S Ratio | 9.2x |
|---|---|
| Forward P/S | 8.7x |
| P/B Ratio | 16.6x |
| P/TBV Ratio | 17.9x |
Price Statistics
The stock is up 97.44% over 52 weeks and trades 32.36% below its 50-day average.
| Beta (1Y) | 1.68 |
|---|---|
| 52-Week Change | +97.44% |
| 1-Month Change | -41.15% |
| 3-Month Change | -27.59% |
| 6-Month Change | -36.28% |
| Total Return (1Y) | +97.44% |
| Total Return (3Y CAGR) | +24.91% |
| Return vs SPY (1Y) | +80.94% |
| Max Drawdown (1Y) | -47.56% |
| Max Drawdown (3Y) | -57.89% |
| Sharpe Ratio (1Y) | 0.90 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $6.83 |
| 200-Day Average | $6.75 |
| 52-Week Range | $2.21 to $9.33 |
| RSI (14 Days) | 25.9 |
| Average Volume (20 Days) | 146.58K |
Financial Position
Current assets cover 2.10x current liabilities, and total debt is 0.06x shareholder equity.
| Current Ratio | 2.10x |
|---|---|
| Quick Ratio | 2.01x |
| Debt / Equity | 0.06x |
| Interest Coverage | -126.72x |
Returns and Efficiency
Return on invested capital is -247.67% and return on equity is -334.07% over the last 12 months.
| Return on Equity (ROE) | -334.07% |
|---|---|
| Return on Assets (ROA) | -181.84% |
| Return on Invested Capital (ROIC) | -247.67% |
| Return on Capital Employed (ROCE) | -318.72% |
| Asset Turnover | 1.05x |
| Inventory Turnover | 3.40x |
| Receivables Turnover | 10.52x |
| Cash Conversion Cycle | -98 days |
Scores
NRXS has an Altman Z-Score of -8.60, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -8.60 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $6.53M over the last 12 months is up 94.29% from the 12 months before.
| Revenue | $6.53M |
|---|---|
| Revenue Growth (YoY) | +94.29% |
| Gross Profit | $5.63M |
| Operating Income | -$12.16M |
| Pretax Income | -$12.10M |
| Net Income | -$12.10M |
| EBITDA | -$11.93M |
| EBIT | -$12.01M |
| Reported EPS (TTM) | -$0.99 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 54.35% of the $6.66M in total assets.
| Cash and Equivalents | $4.48M |
|---|---|
| Total Debt | $207.31K |
| Net Cash | $4.27M |
| Net Cash Per Share | $0.33 |
| Working Capital | $3.16M |
| Shareholder Equity | $3.62M |
| Book Value Per Share | $0.28 |
| Tangible Book Value | $3.36M |
| Tangible Book Per Share | $0.26 |
| Total Assets | $6.66M |
| Total Liabilities | $3.03M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$6.46M |
|---|---|
| FCF Per Share | -$0.52 |
| Depreciation and Amortization | $73.84K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -186.16%.
| Gross Margin | 86.16% |
|---|---|
| Operating Margin | -186.16% |
| Pretax Margin | -185.24% |
| Net Margin | -185.24% |
| EBITDA Margin | -182.66% |
| EBIT Margin | -183.79% |
| Gross Margin (5Y Average) | 86.03% |
Growth
Revenue grew 9.96% a year over 3 years.
| Revenue Growth (3Y CAGR) | +9.96% |
|---|---|
| Revenue Growth (5Y CAGR) | +13.08% |
Peer Position
Against 6 similar companies, NRXS has the 4th highest P/S.
P/S RatioPeer median 16.7x
ROICPeer median -260.49%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -99.99%
| P/S Ratio | 9.2x vs 16.7x median |
|---|---|
| ROIC | -247.67% vs -260.49% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +94.29% vs -99.99% median |
Analyst Forecast
Consensus estimates put revenue growth at 109.73% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +109.73% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NRXS
What is NRXS's market cap?
Neuraxis has a market cap of $68.13M. Its enterprise value, which adds debt and subtracts cash, is $63.86M.
How many shares of NRXS are outstanding?
Neuraxis has 12.99M shares outstanding. The count is up 31.45% from a year earlier.
Does NRXS pay a dividend?
No. Neuraxis does not pay a dividend.
How much debt does NRXS have?
Neuraxis has $207.31K of total debt and $4.48M of cash and equivalents, a net cash position of $4.27M.
NRXS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts